Pre-market hot trades in US stocks: High Roller Tech pre-market down 12.84%; Leifras pre-market down 12.83%

Pre-market Hot Trades in US Stocks High Roller Tech, down 12.84% in pre-market, has no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Leifras, down 12.83% in pre-market, has no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Top Gainers in Pre-market US Stocks Acco, up 174.25% in pre-market. There is no significant news recently; trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news Venus Concept, up 95.80% in pre-market, has no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Jaguar Health, up 36.04% in pre-market. Based on recent key news: On January 15, Jaguar Health signed a licensing agreement with Woodward Specialty LLC, where Woodward will pay Napo Company $18 million, with $16 million paid upon the agreement's effectiveness. This agreement brings significant capital inflow to the company, driving the stock price up. Source: Reuters On January 14, Jaguar Health updated recent catalysts at the Lytham Partners Healthcare Investor Summit, where CEO Lisa Conte gave a virtual presentation. The market is optimistic about the company's future development, positively impacting the stock price. Source: Public Technologies On January 12, Jaguar Health signed a manufacturing and supply agreement with Woodward Specialty to ensure the commercial supply of Mytesi in the United States. This agreement enhances market confidence in the company's product supply chain, further driving the stock price up. Source: SEC Filing. Recent policy support in the pharmaceutical industry has led to significant capital inflow